378 related articles for article (PubMed ID: 26652033)
1. Novel therapeutic interventions for p53-altered tumors through manipulation of its family members, p63 and p73.
Venkatanarayan A; Raulji P; Norton W; Flores ER
Cell Cycle; 2016; 15(2):164-71. PubMed ID: 26652033
[TBL] [Abstract][Full Text] [Related]
2. IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo.
Venkatanarayan A; Raulji P; Norton W; Chakravarti D; Coarfa C; Su X; Sandur SK; Ramirez MS; Lee J; Kingsley CV; Sananikone EF; Rajapakshe K; Naff K; Parker-Thornburg J; Bankson JA; Tsai KY; Gunaratne PH; Flores ER
Nature; 2015 Jan; 517(7536):626-30. PubMed ID: 25409149
[TBL] [Abstract][Full Text] [Related]
3. One, two, three--p53, p63, p73 and chemosensitivity.
Müller M; Schleithoff ES; Stremmel W; Melino G; Krammer PH; Schilling T
Drug Resist Updat; 2006 Dec; 9(6):288-306. PubMed ID: 17287142
[TBL] [Abstract][Full Text] [Related]
4. Alterations of p63 and p73 in human cancers.
Inoue K; Fry EA
Subcell Biochem; 2014; 85():17-40. PubMed ID: 25201187
[TBL] [Abstract][Full Text] [Related]
5. p63 and p73 do not contribute to p53-mediated lymphoma suppressor activity in vivo.
Perez-Losada J; Wu D; DelRosario R; Balmain A; Mao JH
Oncogene; 2005 Aug; 24(35):5521-4. PubMed ID: 16007185
[TBL] [Abstract][Full Text] [Related]
6. Differential regulation of p63 and p73 expression.
Waltermann A; Kartasheva NN; Dobbelstein M
Oncogene; 2003 Aug; 22(36):5686-93. PubMed ID: 12944917
[TBL] [Abstract][Full Text] [Related]
7. TP53 family members and human cancers.
Bénard J; Douc-Rasy S; Ahomadegbe JC
Hum Mutat; 2003 Mar; 21(3):182-91. PubMed ID: 12619104
[TBL] [Abstract][Full Text] [Related]
8. Identification of DeltaN isoform and polyadenylation site choice variants in molluscan p63/p73-like homologues.
Muttray AF; Cox RL; Reinisch CL; Baldwin SA
Mar Biotechnol (NY); 2007; 9(2):217-30. PubMed ID: 17242983
[TBL] [Abstract][Full Text] [Related]
9. The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network.
Boominathan L
Cancer Metastasis Rev; 2010 Dec; 29(4):613-39. PubMed ID: 20922462
[TBL] [Abstract][Full Text] [Related]
10. p63 and p73: roles in development and tumor formation.
Moll UM; Slade N
Mol Cancer Res; 2004 Jul; 2(7):371-86. PubMed ID: 15280445
[TBL] [Abstract][Full Text] [Related]
11. Expression of the p53 family of proteins in central and peripheral human corneal endothelial cells.
Paull AC; Whikehart DR
Mol Vis; 2005 May; 11():328-34. PubMed ID: 15889017
[TBL] [Abstract][Full Text] [Related]
12. p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue.
Lo Iacono M; Monica V; Saviozzi S; Ceppi P; Bracco E; Papotti M; Scagliotti GV
J Thorac Oncol; 2011 Mar; 6(3):473-81. PubMed ID: 21289519
[TBL] [Abstract][Full Text] [Related]
13. Expression profiles of p53, p63, and p73 in benign salivary gland tumors.
Weber A; Langhanki L; Schütz A; Gerstner A; Bootz F; Wittekind C; Tannapfel A
Virchows Arch; 2002 Nov; 441(5):428-36. PubMed ID: 12447671
[TBL] [Abstract][Full Text] [Related]
14. A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma.
Ory B; Ramsey MR; Wilson C; Vadysirisack DD; Forster N; Rocco JW; Rothenberg SM; Ellisen LW
J Clin Invest; 2011 Feb; 121(2):809-20. PubMed ID: 21293058
[TBL] [Abstract][Full Text] [Related]
15. Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma.
DeYoung MP; Johannessen CM; Leong CO; Faquin W; Rocco JW; Ellisen LW
Cancer Res; 2006 Oct; 66(19):9362-8. PubMed ID: 17018588
[TBL] [Abstract][Full Text] [Related]
16. The p53/p63/p73 family of transcription factors: overlapping and distinct functions.
Levrero M; De Laurenzi V; Costanzo A; Gong J; Wang JY; Melino G
J Cell Sci; 2000 May; 113 ( Pt 10)():1661-70. PubMed ID: 10769197
[TBL] [Abstract][Full Text] [Related]
17. P53 family: at the crossroads in cancer therapy.
Alsafadi S; Tourpin S; André F; Vassal G; Ahomadegbe JC
Curr Med Chem; 2009; 16(32):4328-44. PubMed ID: 19754415
[TBL] [Abstract][Full Text] [Related]
18. Expression of p53 and its homologues in primary and recurrent squamous cell carcinomas of the head and neck.
Weber A; Bellmann U; Bootz F; Wittekind C; Tannapfel A
Int J Cancer; 2002 May; 99(1):22-8. PubMed ID: 11948487
[TBL] [Abstract][Full Text] [Related]
19. Cross-talks in the p53 family: deltaNp63 is an anti-apoptotic target for deltaNp73alpha and p53 gain-of-function mutants.
Lanza M; Marinari B; Papoutsaki M; Giustizieri ML; D'Alessandra Y; Chimenti S; Guerrini L; Costanzo A
Cell Cycle; 2006 Sep; 5(17):1996-2004. PubMed ID: 16931914
[TBL] [Abstract][Full Text] [Related]
20. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family.
Flores ER; Sengupta S; Miller JB; Newman JJ; Bronson R; Crowley D; Yang A; McKeon F; Jacks T
Cancer Cell; 2005 Apr; 7(4):363-73. PubMed ID: 15837625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
